rs121912771
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong
The NM_000494.4(COL17A1):c.3908G>A(p.Arg1303Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000123 in 1,613,258 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.00016 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00012 ( 1 hom. )
Consequence
COL17A1
NM_000494.4 missense
NM_000494.4 missense
Scores
4
15
Clinical Significance
Conservation
PhyloP100: 0.491
Genes affected
COL17A1 (HGNC:2194): (collagen type XVII alpha 1 chain) This gene encodes the alpha chain of type XVII collagen. Unlike most collagens, collagen XVII is a transmembrane protein. Collagen XVII is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane. Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa. Two homotrimeric forms of type XVII collagen exist. The full length form is the transmembrane protein. A soluble form, referred to as either ectodomain or LAD-1, is generated by proteolytic processing of the full length form. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PP5
Variant 10-104034193-C-T is Pathogenic according to our data. Variant chr10-104034193-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 17650.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL17A1 | NM_000494.4 | c.3908G>A | p.Arg1303Gln | missense_variant | 52/56 | ENST00000648076.2 | NP_000485.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL17A1 | ENST00000648076.2 | c.3908G>A | p.Arg1303Gln | missense_variant | 52/56 | NM_000494.4 | ENSP00000497653.1 | |||
COL17A1 | ENST00000369733.8 | c.3662G>A | p.Arg1221Gln | missense_variant | 47/51 | 5 | ENSP00000358748.3 |
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152200Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
24
AN:
152200
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000108 AC: 27AN: 249846Hom.: 0 AF XY: 0.000111 AC XY: 15AN XY: 135182
GnomAD3 exomes
AF:
AC:
27
AN:
249846
Hom.:
AF XY:
AC XY:
15
AN XY:
135182
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000120 AC: 175AN: 1460940Hom.: 1 Cov.: 33 AF XY: 0.000118 AC XY: 86AN XY: 726748
GnomAD4 exome
AF:
AC:
175
AN:
1460940
Hom.:
Cov.:
33
AF XY:
AC XY:
86
AN XY:
726748
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000158 AC: 24AN: 152318Hom.: 0 Cov.: 32 AF XY: 0.0000940 AC XY: 7AN XY: 74478
GnomAD4 genome
AF:
AC:
24
AN:
152318
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
74478
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
19
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 06, 2021 | Published functional studies demonstrate a damaging effect of the R1303Q variant on keratinocyte adhesion and collagen XVII-laminin interactions (Kroeger et al., 2019); In silico analysis, which includes splice predictors and evolutionary conservation, supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 31589614, 26604146, 9199555, 17263807, 21466533, 33393081, 23550562, 24005051, 30316981) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 11, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 24, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1303 of the COL17A1 protein (p.Arg1303Gln). This variant is present in population databases (rs121912771, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of junctional epidermolysis bullosa (PMID: 21466533, 23550562, 24005051, 26604146). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 17650). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on COL17A1 function (PMID: 26604146). For these reasons, this variant has been classified as Pathogenic. - |
COL17A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 04, 2024 | The COL17A1 c.3908G>A variant is predicted to result in the amino acid substitution p.Arg1303Gln. This variant has been reported in the homozygous and compound heterozygous states in individuals with junctional epidermolysis bullosa (Schumann et al. 1997. PubMed ID: 9199555; Condrat et al. 2019. PubMed ID: 30761300; Hérissé et al. 2021. PubMed ID: 33393081). In vitro functional studies using patient keratinocytes demonstrated this variant resides in the laminin-332 binding site and results in diminished cell adhesion and impaired migration (Kroeger et al. 2018. PubMed ID: 30316981). This variant is reported in 0.026% of alleles in individuals of European (non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Epidermolysis bullosa, junctional 4, intermediate Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 1997 | - - |
Epithelial recurrent erosion dystrophy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Benign
DEOGEN2
Benign
.;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;.;T
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D
MetaSVM
Benign
T
MutationAssessor
Benign
.;L;L
PrimateAI
Benign
T
PROVEAN
Benign
N;N;.
REVEL
Uncertain
Sift
Benign
T;T;.
Sift4G
Benign
T;T;.
Polyphen
0.71
.;P;P
Vest4
MVP
MPC
0.075
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: 2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at